




RealRate

PHARMACEUTICAL 2020

Iterum Therapeutics plc Rank 338 of 358





RealRate

PHARMACEUTICAL 2020

Iterum Therapeutics plc Rank 338 of 358



The relative strengths and weaknesses of Iterum Therapeutics plc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Iterum Therapeutics plc compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 55% points. The greatest weakness of Iterum Therapeutics plc is the variable Assets, Current, reducing the Economic Capital Ratio by 262% points.

The company's Economic Capital Ratio, given in the ranking table, is -381%, being 418% points below the market average of 36%.

Input Variable	Value in 1000 USD
Assets, Current	11,718
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	36,986
Liabilities, Non-Current	15,003
Other Assets	13,461
Other Compr. Net Income	0
Other Expenses	444
Other Liabilities	0
Other Net Income	-665
Other Revenues	37
Property and Equipment	572
Research and Development	90,774
Selling, General and Administrative Expense	11,284

Output Variable	Value in 1000 USD
Assets	25,751
Liabilities	51,989
Expenses	102,502
Revenues	37
Stockholders Equity	-26,238
Net Income	-103,130
Comprehensive Net Income	-103,130
Economic Capital Ratio	-381%